Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment

Citations Over Time

Abstract

The present study retrospectively analyzed 96 newly diagnosed acute promyelocytic leukemia (APL) patients with low-intermediate mortality risk to identify the optimum timing to initiate cytotoxic chemotherapy following all-trans retinoic acid (ATRA) administration. Based on white blood cell (WBC) at chemotherapy initiation, the patients were divided into three groups: low WBC (WBC count ≤4×109/l), intermediate WBC (WBC count >4×109/l and 9/l) and high WBC group (WBC count ≥15×109/l). According to the period from ATRA commencement to chemotherapy, 96 patients were further divided into two groups: ≤3 days group (chemotherapy within 3 days of ATRA) and >3 days group (chemotherapy >3 days after ATRA). Clinical effects were compared by univariate analysis and multivariate analyses. The incidence rate of differentiation syndrome (DS; also termed retinoic acid syndrome) was 0.0, 11.1 and 40.0% in the low, intermediate and high WBC groups, respectively (P3 days groups, except in time to achieve CR (P=0.004) and rate of bleeding related to chemotherapy (P=0.009), both being higher in the >3 days group. Multivariate analyses indicated WBC count at chemotherapy was the only independent risk factor for the occurrence of DS [P=0.002; odds ratio (OR) =1.058, 95% confidence interval (CI) =1.021-1.095] and early mortality (P=0.036; OR =1.036, 95% CI =1.002-1.070). For newly diagnosed APL patients with low-intermediate risk, chemotherapy initiation should be recommended until WBC count rises to between 4×109/l and 15×109/l during induction treatment.

Related Papers

• → The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia(1986)83 cited
• → Sweet Syndrome Developing During Treatment With All-Trans Retinoic Acid in a Child With Acute Myelogenous Leukemia(2004)22 cited
• → The Role of All-<i>Tran</i><i>s</i>-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia(1993)12 cited
• → Treatment of acute promyelocytic leukemia with all-trans retinoic acid(2000)12 cited
• Effect of arsenious acid and all-trans retinoic acid in combination with chemotherapy on acute promyelocytic leukemia(2010)